The vast majority of prescription drug expenditures are now managed by private and government third-party payors. Drug manufacturers cannot afford to overlook the strategic importance of payors in today’s marketplace nor the tremendous influence they can have on the commercial performance of pharmaceutical and biotech products.

Coram has more than 850 active contracts with a variety of commercial payors, including traditional health insurers, managed care organizations, preferred provider organizations, third-party administrators, at-risk health providers, self-insured plans, provider network managers, and more. These contracts include covered lives in all states, and Coram estimates that its contracts currently cover more than 75% of the commercially insured lives in the United States, or approximately 175 million people.